Print Page     Close Window     

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
April 26, 2017BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
Conference Call and Webcast on Wednesday, May 10, 2017, at 4:30 p.m. ET / 1:30 p.m. PT ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release first quarter financial and operating results on Wednesday, May 10, 2017, after the close of the U.S. financial markets. The Compa... 
Printer Friendly Version
April 24, 2017BioTime to Present Additional Data at Upcoming ARVO
Retinal tissue regeneration presentation added OpRegen® presentation scheduled for May 8 ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 24, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the Annual Meeting of ... 
Printer Friendly Version
April 06, 2017BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
Objective is to quickly establish leadership in the emerging biotechnology field of Aging through pluripotency and iTR™ assets BioTime continues execution of corporate simplification strategy while remaining focused on Ophthalmology, Aesthetics and Therapeutics Delivery ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 6, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing... 
Printer Friendly Version
April 04, 2017BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company’s Plans to Develop Applications in Human Aging ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 4, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a keynote presentation at the GT... 
Printer Friendly Version
March 28, 2017Key BioTime Patents Upheld by European Patent Office
EPO Rules Patents for OpRegen® are Valid and Remain in Force as Granted OpRegen® is in Development to Treat Dry-AMD ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 28, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company developing and commercializing products addressing degenerative disease, today announced the successful defense of two key patents from challenge before the European Patent Office (EPO) Opposition divisio... 
Printer Friendly Version
March 20, 2017BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Oppenheimer 27th Annual Healthcare Conference at the Westin Grand Central in New York City on March 21, at 3:55 p.m. Eastern Time. A webcast of Mr. Skibsted’s ... 
Printer Friendly Version
March 16, 2017BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Conference Call and Webcast Today at 4:30 p.m. Eastern Time ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 16, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the fourth quarter and year ended December 31, 2016. “I’m happy with the tremendous progress we made last year in all three of our strategi... 
Printer Friendly Version
March 15, 2017Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 15, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase I/IIa clinical trial of OpRegen® in the advanced form of dry age-related macular degeneration (dry-AMD) will be presented at the Annual Meeting of the Association for Research in Vision ... 
Printer Friendly Version
March 13, 2017BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen® in the advanced dry form age-related macular degeneration (dry-AMD) by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical... 
Printer Friendly Version
February 23, 2017BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 23, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial and operating results on Thursday, March 16, 2017, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, March 16, 2017, at 4:30 ... 
Printer Friendly Version
February 21, 2017BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 21, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.’s financial statements from BioTime’s consolidated financial statements effective February 17, 2017. As a result of the deconsolidation, BioTime will report a pro forma, non-cash gain of approximately $56 million... 
Printer Friendly Version
February 15, 2017BioTime, Inc. Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2017-- BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,453,704, shares of its common stock in the offering, which includes 972,222 shares of its common stock issued in connection with the ... 
Printer Friendly Version
February 15, 2017CORRECTING and REPLACING BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 15, 2017-- Please replace the release dated February 6, 2017, with the following corrected version due to multiple revisions. The corrected release reads: BIOTIME EXPANDS OPHTHALMOLOGY PORTFOLIO WITH GLOBAL IN-LICENSING AGREEMENT FOR NEXT-GENERATION RET... 
Printer Friendly Version
February 13, 2017BioTime to Present at Two Upcoming Investor Conferences
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 13, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 14, at 2:30 p.m. Eastern Time, and at the Disruptive Growth Confer... 
Printer Friendly Version
February 10, 2017BioTime, Inc. Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 10, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of 6,481,482 shares of its common stock at a public offering price of $2.70 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $... 
Printer Friendly Version
February 09, 2017BioTime, Inc. Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Feb. 9, 2017-- BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. BioTime, Inc. also expects to grant to the underwriters for the offering a 30-day option to purchase up to an additional 15% of the n... 
Printer Friendly Version
February 07, 2017BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel
Draws on a Deep Background at Leading Life Sciences Companies ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Stephana Patton, Ph.D., J.D., as General Counsel, a newly created position. Reporting in her new role to Adi Mohanty, Co-CEO, Dr. Patton will oversee ... 
Printer Friendly Version
February 06, 2017BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh Medical Center
Advanced retinal regeneration program could lead to fully functional retinal tissue implants to restore vision in late stages of blindness ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the acquisition of global rights to ophthalmology-related intellectual property (IP) assets from the Univer... 
Printer Friendly Version
January 26, 2017BioTime to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 26, 2017-- BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the NobleCon13 - Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort & Club in Boca Raton, Florida, on Monday, January 30, at 11:00 a.m. Eastern Standard Tim... 
Printer Friendly Version
January 19, 2017Additional Data From BioTime’s OpRegen® Clinical Trial in Dry-AMD to be Presented at ARVO 2017
-Data from patients in Cohort 1 and Cohort 2 to be presented- ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 19, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd., today announced that an abstract evaluating OpRegen® in patients with advanced dry Age-Related Macular Degeneration (dry-AMD) based on the ongoing Phase I/IIa clinical tr... 
Printer Friendly Version
January 03, 2017BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
-Supplying OpRegen® for the Ongoing Clinical Trial for the Treatment of Dry Age-Related Macular Degeneration- -Center has Capability to Manufacture Additional BioTime Products- ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--Jan. 3, 2017-- BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cel... 
Printer Friendly Version

© Copyright BioTime, Inc.